21:19 , Oct 15, 2018 |  BC Extra  |  Preclinical News

mAb blocks fibrin's inflammation without clotting interference to treat MS, Alzheimer's

Gladstone Institutes researchers developed a mAb that could help treat neurodegenerative and autoimmune CNS diseases such as multiple sclerosis or Alzheimer's disease by specifically blocking the proinflammatory effects of fibrin without compromising its clotting ability. In...
19:27 , Sep 10, 2018 |  BC Innovations  |  Distillery Techniques

Drug delivery

TECHNOLOGY: Nanoparticles Nanoparticles bound to red blood cells (RBCs) could be used to deliver drugs to the vasculature of specific organs. The method involves mixing bare nanogels with ex vivo RBCs to enable RBC-nanoparticle binding, then...
17:25 , Feb 16, 2018 |  BC Week In Review  |  Clinical News

Ergomed's PeproStat meets in Phase II for intraoperative surgical bleeding

In October, Ergomed plc (LSE:ERGO) reported top-line data from a Phase II trial to treat intraoperative surgical bleeding in 169 patients undergoing liver/soft tissue, vascular or spinal surgery showing that PeproStat met the primary endpoint...
20:33 , Nov 6, 2017 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Multiple sclerosis (MS) Patient sample and mouse studies suggest inhibiting fibrinogen could help treat MS. In postmortem brain tissue samples from MS patients, levels of perivascular fibrinogen were higher in chronic MS lesions than in...
15:08 , Sep 1, 2017 |  BC Week In Review  |  Clinical News

Ergomed completes enrollment in Ph IIb of PeproStat

Ergomed plc (LSE:ERGO) completed enrollment of >160 patients undergoing liver, soft tissue, vascular or spinal surgery in a Phase IIb trial of PeproStat to treat intraoperative surgical bleeding. The primary endpoint for the double-blind, placebo-controlled,...
23:27 , Aug 17, 2017 |  BC Innovations  |  Targets & Mechanisms

GRP-THINK AT THE BBB

Biogen Inc. has discovered antibodies in patients with a rare CNS autoimmune disease that could provide a new way to deliver mAbs across the blood-brain barrier, an application with wide-reaching ramifications for neurologic drug development. The...
20:31 , Jun 16, 2017 |  BC Week In Review  |  Company News

CSL buying majority stake in Chinese plasma company

CSL Ltd. (ASX:CSL) said it is acquiring an 80% stake in plasma therapy company Wuhan Zhong Yuan Rui De Biological Products Co. Ltd. (Ruide) for $352 million. Ruide is a subsidiary of Humanwell Healthcare Group...
20:18 , Jun 13, 2017 |  BC Extra  |  Company News

CSL buying majority stake in Chinese plasma company

CSL Ltd. (ASX:CSL) said it is acquiring an 80% stake in plasma therapy company Wuhan Zhong Yuan Rui De Biological Products Co. Ltd. (Ruide) for $352 million. Ruide is a subsidiary of Humanwell Healthcare Group...
00:26 , Apr 15, 2017 |  BioCentury  |  Product Development

Outside factors

This year could see the first regulatory submission from a coming wave of new therapies for hemophilia prophylaxis that do not simply replace missing clotting factors, which has been the standard for care for decades....
00:59 , Mar 30, 2017 |  BC Week In Review  |  Clinical News

PeproStat: Ph II started

Ergomed began a double-blind, placebo-controlled, European Phase IIb trial to evaluate topical PeproStat in about 120 patients undergoing liver, soft tissue, vascular or spinal surgery. Ergomed plc (LSE:ERGO), Guilford, U.K.  Product: PeproStat  Business: Hematology  Molecular target: Fibrinogen  Description: Peptide-based hemostat...